Contact Us
Drug Search Results
More Filters [+]

BGB-R046

Alternative Names: BGB-R046, BGB R046, BGBR046
Latest Update: 2024-08-07
Latest Update Note: News Article

Product Description

Mechanisms of Action: IL15 Modulator

Novel Mechanism: Yes

Modality: Cytokine

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BGB-R046

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BGB-R046-101

P1

Recruiting

Oncology Solid Tumor Unspecified

2027-12-01

Recent News Events

Date

Type

Title

08/07/2024

News Article

 BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions